Yazar "Abavisani, Mohammad" seçeneğine göre listele

Listeleniyor 1 - 7 / 7
  • [ X ]
    Öğe
    Beyond the Hayflick limit: How microbes influence cellular aging
    (Elsevier Ireland Ltd, 2025) Abavisani, Mohammad; Faraji, Saba; Ebadpour, Negar; Karav, Sercan; Sahebkar, Amirhossein
    Cellular senescence, a complex biological process resulting in permanent cell-cycle arrest, is central to aging and age-related diseases. A key concept in understanding cellular senescence is the Hayflick Limit, which refers to the limited capacity of normal human cells to divide, after which they become senescent. Senescent cells (SC) accumulate with age, releasing pro-inflammatory and tissue-remodeling factors collectively known as the senescence-associated secretory phenotype (SASP). The causes of senescence are multifaceted, including telomere attrition, oxidative stress, and genotoxic damage, and they extend to influences from microbial sources. Research increasingly emphasizes the role of the microbiome, especially gut microbiota (GM), in modulating host senescence processes. Beneficial microbial metabolites, such as short-chain fatty acids (SCFAs), support host health by maintaining antioxidant defenses and reducing inflammation, potentially mitigating senescence onset. Conversely, pathogenic bacteria like Pseudomonas aeruginosa and Helicobacter pylori introduce factors that damage host DNA or increase ROS, accelerating senescence via pathways such as NF-?B and p53-p21. This review explores the impact of bacterial factors on cellular senescence, highlighting the role of specific bacterial toxins in promoting senescence. Additionally, it discusses how dysbiosis and the loss of beneficial microbial species further contribute to age-related cellular deterioration. Modulating the gut microbiome to delay cellular senescence opens a path toward targeted anti-aging strategies. This work underscores the need for deeper investigation into microbial influence on aging, supporting innovative interventions to manage and potentially reverse cellular senescence. © 2025 Elsevier B.V.
  • [ X ]
    Öğe
    Exosome/Extracellular Vesicles-Based Therapeutics in Alzheimer's Disease: Neuroprotective Roles and Future Perspectives
    (Springernature, 2025) Ebadpour, Negar; Abavisani, Mohammad; Karav, Sercan; Kesharwani, Prashant; Sahebkar, Amirhossein
    Alzheimer's disease (AD), a progressive neurodegenerative disorder, is marked by memory loss, cognitive decline, and characteristic pathological features including beta-amyloid (A beta) plaques, tau tangles, and neuroinflammation. Despite extensive research, effective therapies remain elusive. Exosome/EVs-based therapeutics have emerged as a promising avenue for AD treatment. Neuron-derived exosomes/extracellular vesicles (EVs) (NDEs) and stem cell-derived exosomes/EVs exhibit neuroprotective effects by promoting A beta degradation, modulating tau pathology, and reducing inflammation. Notably, NDEs carry insulin-degrading enzyme (IDE) and cellular prion proteins (PrPC), aiding A beta clearance. However, exosomes also present challenges, such as the potential propagation of pathogenic tau and complement-mediated neurotoxicity. Neural and mesenchymal stem cell-derived exosomes further demonstrate therapeutic efficacy by altering amyloid precursor protein processing and activating PI3K/Akt/mTOR signaling to reduce AD pathology. Despite these advancements, clinical translation requires a deeper understanding of exosome/EVs biology, improved isolation techniques, and personalized strategies. Continued research may establish exosomes as a transformative approach in AD therapy.
  • [ X ]
    Öğe
    Mechanisms, Modulation, and Mitigation: Dietary-Gut Microbiome Strategies Against Antibiotic Resistance
    (Springer, 2025) Abavisani, Mohammad; Khoshroo, Niloofar; Tafti, Pourya; Foroushan, Sobhan Karbas; Ebadpour, Negar; Karav, Sercan; Kesharwani, Prashant
    Antibiotic resistance seriously compromises world health by affecting the effectiveness of therapies and greatly raising morbidity, death, and healthcare expenditures. Particularly in hospital environments, the rapid spread of multidrug-resistant organisms hampers the treatment of bacterial infections and challenges the efficacy of current medicines. Antibiotic resistance has multiple mechanisms: biofilm development, horizontal gene transfer, and genetic alterations. To address this developing issue, studies have focused on alternative strategies, including new antimicrobial medicines, combination treatments, and non-traditional remedies. Additionally, dietary therapies, probiotics (the live microorganisms that, when administered in adequate amounts, confer a health benefit on the host), and phytochemicals have garnered interest due to their ability to alter the gut microbiota, the complex community of microorganisms living in the digestive tracts, thus potentially limiting the dissemination of resistant bacteria. These approaches, meanwhile, have difficulties, including limits in clinical translation and the adaptation of bacterial populations. This study aims to comprehensively review the current understanding of the connections between the gut microbiome and the development of antibiotic resistance by investigating the probable underlying mechanistic effects and also highlights the possibility of targeting host-microbiome interactions as a new intervention option.
  • [ X ]
    Öğe
    Mechanistic insights into postbiotics as therapeutic agents in type 2 diabetes management
    (Springer, 2025) Ebadpour, Negar; Faraji, Navid; Abavisani, Mohammad; Karav, Sercan; Sahebkar, Amirhossein
    The rising prevalence of type 2 diabetes mellitus (T2DM) alongside its associated morbidity and complications underscores the need for adjunctive therapies beyond glycemic control and lifestyle modification. Emerging evidence implicates gut microbiota-derived metabolites in the modulation of host energy homeostasis. One of these metabolites, postbiotics-the bioactive substances created during the fermentation of probiotics-have now become a promising therapeutic. Postbiotics, which contain short-chain fatty acids (SCFAs), exopolysaccharides (EPS), peptidoglycans, bacteriocins, vitamins, and neurotransmitters, have numerous mechanisms that regulate glucometabolism, improve insulin sensitivity, and are able to attenuate systemic inflammation. These compounds are able to regulate insulin receptor signaling and hepatic glucose production by modulating such key metabolic pathways as glycolysis and gluconeogenesis. Based on the previous preclinical and clinical evidence, postbiotic compounds exhibit mechanistic plausibility as adjunct therapies for T2DM. However, due to heterogeneity in patient microbiomes and a lack of standardized formulations that limit current applicability, further investigations are required. Future investigations should focus on dose-finding, long-term safety, and stratification of responders based on microbial and metabolic phenotypes. This review explores the role of postbiotics in T2DM from a mechanistic point of view, highlights their clinical significance in T2DM management, and discusses the next avenue to improve the therapeutic approaches.
  • Küçük Resim
    Öğe
    Overcoming antibiotic resistance: the potential and pitfalls of drug repurposing
    (Taylor & Francis Ltd, 2024) Abavisani, Mohammad; Khoshrou, Alireza; Eshaghian, Souzan; Karav, Sercan; Sahebkar, Amirhossein
    Since its emergence shortly after the discovery of penicillin, antibiotic resistance has escalated dramatically, posing a significant health threat and economic burden. Drug repositioning, or drug repurposing, involves identifying new therapeutic applications for existing drugs, utilising their established safety profiles and pharmacological data to swiftly provide effective treatments against resistant pathogens. Several drugs, including otilonium bromide, penfluridol, eltrombopag, ibuprofen, and ceritinib, have demonstrated potent antibacterial activity against multidrug-resistant (MDR) bacteria. These drugs can disrupt biofilms, damage bacterial membranes, and inhibit bacterial growth. The combination of repurposed drugs with conventional antibiotics can reduce the required dosage of individual drugs, mitigate side effects, and delay the development of resistance, making it a promising strategy against MDR bacteria such as Staphylococcus aureus, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Escherichia coli. Despite its promise, drug repurposing faces challenges such as potential off-target effects, toxicity, and regulatory and intellectual property issues, necessitating rigorous evaluations and strategic solutions. This article aims to explore the potential of drug repurposing as a strategy to combat antibiotic resistance, examining its benefits, challenges, and future prospects. We address the legal, economic, and practical challenges associated with repurposing existing drugs, highlight successful examples, and propose solutions to enhance the efficacy and viability of this approach in combating MDR bacterial infections.
  • [ X ]
    Öğe
    RNA-based antibacterial agents: Mechanisms, functional insights, and challenges in therapeutic development
    (Elsevier Science Sa, 2025) Abavisani, Mohammad; Sajjadi, Seyed Mohammad; Ebadpour, Negar; Kesharwani, Prashant; Karav, Sercan; Sahebkar, Amirhossein
    Antibacterial resistance is a vivified worldwide problem of health care. RNA-based antibacterial agents, on the other hand, present a new method of using mechanisms such as RNA interference (RNAi), riboswitch regulation, clustered regularly interspaced short palindromic repeats (CRISPR)- CRISPR-associated protein (Cas) systems, and antisense oligonucleotides (ASOs) to the max. CRISPR-Cas systems allow opportunity to cure targeted region of a resistant gene or cut it out completely, which is a highly adaptable method for treating multidrug-resistant (MDR) bacteria. ASOs, along with peptide nucleic acids (PNAs) and phosphorodiamidate morpholino oligomers (PMOs), are substances that stop bacterial gene expression, thus, minimizing the pathogenicity. Nevertheless, their promise is put down because of problems such as delivery efficiency, molecular stability, and off-target effects that come with these. Innovations in chemical changes and delivery technologies have resulted in the development of the stable and targeted delivery of RNA-based agents. This study takes a close look at the mechanisms, therapeutic potential, and challenges of RNA-based antibacterials and stresses their ability to be the most successful tools in combating antibiotic resistance. The combination of these strategies with the existing antibiotics could increase their efficacy, make it possible for us to address resistance and open new ways for antibacterial therapies.
  • [ X ]
    Öğe
    The road less traveled: Unexplored targets in the quest for antibiotics against Pseudomonas aeruginosa
    (Pergamon-Elsevier Science Ltd, 2025) Abavisani, Mohammad; Fazeli, Erfan; Ebadpour, Negar; Karav, Sercan; Kesharwani, Prashant; Sahebkar, Amirhossein
    Pseudomonas aeruginosa, an opportunistic pathogen known for its adaptability, has become a critical health concern due to its inherent resistance to multiple antibiotic classes and its rapid acquisition of new resistance mechanisms. The rise of multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains has further compounded the global burden of P. aeruginosa infections. Traditional antibiotic discovery efforts, which focus on essential bacterial processes such as cell wall synthesis, protein production, and DNA replication, have been unable to keep pace with the pathogen's evolving resistance strategies. Recent advancements in omics technologies have provided deeper insights into the complex biology of P. aeruginosa, including bacterial communication networks like quorum sensing and interactions between the host and pathogen that are crucial for the pathogen's survival and virulence. These insights pave the way for identifying novel therapeutic targets, such as unexplored metabolic pathways and virulence mechanisms, which could offer more effective strategies for combating resistant P. aeruginosa strains. In this review, we critically assess the limitations of conventional approaches and emphasize the potential of targeting these alternative pathways to address the growing challenge of antibiotic resistance. By exploring innovative strategies that transcend traditional methods, this review underscores the importance of pursuing novel therapeutic avenues that could lead to the development of more effective antibiotics against P. aeruginosa and similar resistant pathogens.